Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 3
2005 1
2006 3
2007 4
2008 3
2009 4
2010 6
2011 9
2012 12
2013 3
2014 3
2015 7
2016 8
2017 2
2018 5
2019 4
2020 2
2021 2
2022 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR, Zarrella DT, Guo M, Minogue E, Lawrence MS, Rueda BR, Spriggs DR, Lu W, Langenau DM, Cobbold M. Zhang S, et al. Among authors: spriggs dr. Cancer Res. 2024 May 2;84(9):1534. doi: 10.1158/0008-5472.CAN-24-0718. Cancer Res. 2024. PMID: 38693893 No abstract available.
Sialyl-Tn serves as a potential therapeutic target for ovarian cancer.
Al-Alem L, Prendergast JM, Clark J, Zarrella B, Zarrella DT, Hill SJ, Growdon WB, Pooladanda V, Spriggs DR, Cramer D, Elias KM, Nazer RI, Skates SJ, Behrens J, Dransfield DT, Rueda BR. Al-Alem L, et al. Among authors: spriggs dr. J Ovarian Res. 2024 Apr 2;17(1):71. doi: 10.1186/s13048-024-01397-1. J Ovarian Res. 2024. PMID: 38566237 Free PMC article.
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Matoba Y, Zarrella DT, Pooladanda V, Azimi Mohammadabadi M, Kim E, Kumar S, Xu M, Qin X, Ray LJ, Devins KM, Kumar R, Kononenko A, Eisenhauer E, Veillard IE, Yamagami W, Hill SJ, Sarosiek KA, Yeku OO, Spriggs DR, Rueda BR. Matoba Y, et al. Among authors: spriggs dr. Br J Cancer. 2024 May;130(9):1463-1476. doi: 10.1038/s41416-024-02621-x. Epub 2024 Mar 4. Br J Cancer. 2024. PMID: 38438589 Free PMC article.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR, Zarrella DT, Guo M, Minogue E, Lawrence MS, Rueda BR, Spriggs DR, Lu W, Langenau DM, Cobbold M. Zhang S, et al. Among authors: spriggs dr. Cancer Res. 2022 Mar 1;82(5):773-784. doi: 10.1158/0008-5472.CAN-21-2200. Cancer Res. 2022. PMID: 34965933
84 results